- 同
- B29, Immunoglobulin p
UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
- 1. BおよびTリンパ球の正常な発生 normal b and t lymphocyte development
- 2. リンパ形質細胞性リンパ腫の臨床症状、病理学的特徴、および診断 clinical manifestations pathologic features and diagnosis of lymphoplasmacytic lymphoma
- 3. 慢性リンパ性白血病の臨床症状、病理学的特徴、診断、および鑑別診断 clinical presentation pathologic features diagnosis and differential diagnosis of chronic lymphocytic leukemia
- 4. Clinical manifestations, pathologic features, and diagnosis of small lymphocytic lymphoma
- 5. 原発性皮膚大細胞型B細胞性リンパ腫、下肢型 primary cutaneous large b cell lymphoma leg type
English Journal
- B-cell-specific conditional expression of Myd88p.L252P leads to the development of diffuse large B-cell lymphoma in mice.
- Knittel G1, Liedgens P1, Korovkina D1, Seeger JM2, Al-Baldawi Y3, Al-Maarri M4, Fritz C1, Vlantis K5, Bezhanova S6, Scheel AH7, Wolz OO8, Reimann M9, Möller P10, López C11, Schlesner M12, Lohneis P13, Weber AN8, Trümper L14; German International Cancer Genome Consortium Molecular Mechanisms in Malignant Lymphoma by Sequencing Project Consortium, Staudt LM15, Ortmann M7, Pasparakis M5, Siebert R11, Schmitt CA16, Klatt AR17, Wunderlich FT4, Schäfer SC7, Persigehl T3, Montesinos-Rongen M18, Odenthal M19, Büttner R20, Frenzel LP21, Kashkar H22, Reinhardt HC23.
- Blood.Blood.2016 Jun 2;127(22):2732-41. doi: 10.1182/blood-2015-11-684183. Epub 2016 Apr 5.
- The adaptor protein MYD88 is critical for relaying activation of Toll-like receptor signaling to NF-κB activation. MYD88 mutations, particularly the p.L265P mutation, have been described in numerous distinct B-cell malignancies, including diffuse large B-cell lymphoma (DLBCL). Twenty-nine percent o
- PMID 27048211
- CD79B limits response of diffuse large B cell lymphoma to ibrutinib.
- Kim JH1, Kim WS1,2, Ryu K1, Kim SJ1,2, Park C1.
- Leukemia & lymphoma.Leuk Lymphoma.2016 Jun;57(6):1413-22. doi: 10.3109/10428194.2015.1113276. Epub 2015 Dec 24.
- Blockage of B cell receptor signaling with ibrutinib presents a promising clinical approach for treatment of B-cell malignancies. However, many patients show primary resistance to the drug or develop secondary resistance. In the current study, cDNA microarray and Western blot analyses revealed CD79B
- PMID 26699656
- IL-4 rescues surface IgM expression in chronic lymphocytic leukemia.
- Guo B1, Zhang L2, Chiorazzi N3, Rothstein TL4.
- Blood.Blood.2016 May 25. pii: blood-2015-11-682997. [Epub ahead of print]
- Chronic lymphocytic leukemia (CLL) cells express poor levels of surface Ig, and many are minimally activated or anergic in response to BCR crosslinking in vitro. Paradoxically, CLL cells in patients are highly activated through BCR signaling and expand in proliferation centers, suggesting that the f
- PMID 27226435
Japanese Journal
- CD22とCD79bを標的とするmonomethyl auristatin E抱合ADCによるB細胞リンパ腫治療 (特集 血液腫瘍に対する抗体医薬のさらなる進展)
- 血液内科 68(4), 470-475, 2014-04
- NAID 40020085498
- Downregulation of the B-cell receptor signaling component CD79b in plasma cell myeloma : A possible post transcriptional regulation
- Pathology international 61(3), 122-129, 2011-03-01
- NAID 10031185060
- Effects of Growth Hormone on the Differentiation of Mouse B-Lymphoid Precursors
- Journal of pharmacological sciences 97(3), 408-416, 2005-03-20
- NAID 10025726963
Related Links
- CD79b抗原（B29,Igβ）は、細胞表面免疫グロブリン（sIg）と会合して B細胞抗原レセプタ（BCR）複合体を形成するMB-1/B29ジスルフィド結合ヘテロダイマーの一部です。CD79b分子は、Igスーパーファミリーに属する分子量33-40kDaの糖 ...
- CD79B Antibody (C-19) is a goat polyclonal IgG provided at 200 µg/ml epitope mapping at the C-terminus of CD79B of human origin recommended for detection of CD79B of mouse, rat and human origin by WB, IP, IF and ELISA; also ...
Related Pictures
![Constitutive activation of the NF-[kappa]B](https://1mg.info/0/7/s/1698.jpg)
★リンクテーブル★
| リンク元 | 「慢性リンパ性白血病」 |
「慢性リンパ性白血病」
- first aid step1 2006 p.300,302,303,304,309,310,427,430
概念
- the accumulation of nonproliferating mature-appearing lymphocytes in the blood, marrow, lymph nodes, and spleen.
- monoclonal B lymphocytes.
- CD5+ and CD23+CD5, CD23
- derived from memory B cell.
細胞表面マーカー WCH.2438
| condition | smIg | CD5 | CD10 | CD11c | CD19 | CD20 | CD22 | CD23 | CD25 | CD43 | CD79b | CD103 | FMC7 |
| chronic lymphocytic leukemia | Dim | ＋＋ | － | －/＋ | ＋＋ | Dim | －/＋ | ＋＋ | ＋/－ | ＋ | － | － | －/＋ |
| Waldenstrom macroglobulinemia | ＋＋ | － | － | －/＋ | ＋＋ | ＋＋ | ＋ | － | －/＋ | ＋/－ | ＋ | － | ＋ |
| prolymphocytic leukemia | ＋＋＋ | －/＋ | －/＋ | －/＋ | ＋＋ | ＋＋＋ | ＋＋ | ＋＋ | －/＋ | ＋ | ＋＋ | － | ＋ |
| hairy cell leukemia | ＋＋＋ | － | － | ＋＋ | ＋＋＋ | ＋＋＋ | ＋＋＋ | － | ＋＋＋ | ＋ | ＋ | ＋＋＋ | ＋＋＋ |
| hairy cell leukemia variant | ＋＋＋ | － | － | ＋＋ | ＋＋＋ | ＋＋＋ | ＋＋＋ | － | － | ＋ | ＋ | ＋＋＋ | ＋＋＋ |
| splenic lymphoma with villous lymphocytes | ＋＋ | －/＋ | －/＋ | ＋/－ | ＋＋ | ＋＋ | ＋＋ | ＋/－ | －/＋ | ＋ | ＋＋ | －/＋ | ＋＋ |
| marginal zone B-cell lymphoma | ＋＋ | － | － | ＋/－ | ＋＋ | ＋＋ | ＋/－ | ＋/－ | － | －/＋ | ＋＋ | － | ＋ |
| mantle cell lymphoma | ＋＋ | ＋＋ | －/＋ | － | ＋＋ | ＋＋ | ＋＋ | － | － | ＋ | ＋＋ | － | ＋＋ |
| follicular lymphoma | ＋＋ | －/＋ | ＋＋ | － | ＋＋ | ＋＋ | ＋＋ | －/＋ | － | － | ＋＋ | － | ＋＋ |
臨床像
- HIM.693
| 年齢 | 子供における頻度 | 男性(%) | ステージI,II vs III,IV(%) | B症状(%) | 骨髄浸潤(%) | 消化管浸潤(%) | 5年生存率(%) | |
| B細胞CLL/小リンパ球性リンパ腫 | 65 | まれ | 53 | 9 vs 91 | 33 | 72 | 3 | 51 |
疫学
- YN.G-49
- 全白血病の2-3%
- 60歳以上に多い。
- 男女比=2:1
病態
- YN.G-49
- 正常な免疫グロブリンの産生が抑制されるばかりでなく、異常な自己抗体を産生 → 続発性免疫不全症、自己免疫性溶血性貧血
USMLE
- Q book p.246 42
参考
- 1. [charged] Epidemiology and clinical manifestations of chronic lymphocytic leukemia - uptodate [1]
- 2. [charged] Pathologic features, diagnosis, and differential diagnosis of chronic lymphocytic leukemia - uptodate [2]
- 3. [charged] Pathophysiology and cytogenetics of chronic lymphocytic leukemia - uptodate [3]